Abbott Laboratories – Consensus Indicates Potential 12.5% Upside

Broker Ratings

Abbott Laboratories with ticker code (ABT) now have 22 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 158 and 109 and has a mean target at 132.28. Now with the previous closing price of 117.57 this indicates there is a potential upside of 12.5%. The 50 day MA is 122.81 and the 200 moving average now moves to 119.52. The company has a market cap of $208,289m. Visit the company website at: http://www.abbott.com

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. It has collaboration agreement with Cereno Scientific AB (publ). The company was founded in 1888 and is based in North Chicago, Illinois.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

You might also enjoy reading  Abbott Laboratories - Consensus Indicates Potential 31.4% Upside
Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index